-- Transforming the "grammar" of drug discovery by focusing on molecular pathways and patient stratification -- Redefining Research-to-Development transition through fast and rigorous "proof-of-concept" trials -- More than 60 new molecular entities have potential to enter trials by end of 2008 -- Development pipeline progressing well, key data planned for second half of 2005 CAMBRIDGE, Mass., May 3, 2005 (PRIMEZONE) -- At an investor conference to highlight progress at the Novartis Institutes for BioMedical Research (NIBR), senior Novartis scientists presented their new research strategy focused on molecular pathways that may be shared by various diseases as an organizing concept in the search for novel compounds that address unmet needs of patients.